Literature DB >> 21537847

Management of meningeal neoplasms: meningiomas and hemangiopericytomas.

Zanetta Lamar1, Glenn J Lesser.   

Abstract

OPINION STATEMENT: Meningiomas are the most frequently diagnosed primary brain tumor accounting for nearly one third of all primary brain and central nervous system tumors reported in the United States. According to the 2007 World Health Organization classification scheme, Grade I meningiomas are benign, Grade II defines atypical lesions, while Grade III meningiomas are anaplastic or frankly malignant tumors. Not surprisingly, Grade II and III meningiomas usually follow a more aggressive course and confer a worse prognosis. The diagnosis of meningioma is confirmed by pathologic examination and improvements in imaging help to better define when observation versus intervention is appropriate. Surgical resection, when possible, is the mainstay of treatment. When complete resection is not possible, stereotactic radiosurgery (SRS) can result in disease stabilization. Chemotherapy has yet to result in reproducible long-term disease free or overall survival benefits. Biologic agents remain under investigation. Hemangiopericytomas are rare dural based sarcomas. These tumors are known for their aggressiveness, high recurrence rates and their proclivity to metastasize to extracranial locations. Gross total resection when feasible remains the treatment of choice.

Entities:  

Mesh:

Year:  2011        PMID: 21537847     DOI: 10.1007/s11864-011-0156-2

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  37 in total

1.  The recurrence of intracranial meningiomas after surgical treatment.

Authors:  D SIMPSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1957-02       Impact factor: 10.154

2.  The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas.

Authors:  Michael E Sughrue; Ari J Kane; Gopal Shangari; Martin J Rutkowski; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  J Neurosurg       Date:  2010-04-09       Impact factor: 5.115

Review 3.  Predictors of mortality following treatment of intracranial hemangiopericytoma.

Authors:  Martin J Rutkowski; Michael E Sughrue; Ari J Kane; Derick Aranda; Steven A Mills; Igor J Barani; Andrew T Parsa
Journal:  J Neurosurg       Date:  2010-08       Impact factor: 5.115

4.  Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up.

Authors:  H B Newton; S R Scott; C Volpi
Journal:  Br J Neurosurg       Date:  2004-10       Impact factor: 1.596

5.  Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas.

Authors:  Michael E Sughrue; Nader Sanai; Gopal Shangari; Andrew T Parsa; Mitchel S Berger; Michael W McDermott
Journal:  J Neurosurg       Date:  2010-08       Impact factor: 5.115

6.  Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.

Authors:  U M Schrell; M G Rittig; M Anders; U H Koch; R Marschalek; F Kiesewetter; R Fahlbusch
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

7.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

Review 8.  Hydroxyurea chemotherapy in the treatment of meningiomas.

Authors:  Herbert B Newton
Journal:  Neurosurg Focus       Date:  2007       Impact factor: 4.047

9.  Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas.

Authors:  Vinay Gupta; Yuzhuang S Su; Christian G Samuelson; Leonard F Liebes; Marc C Chamberlain; Florence M Hofman; Axel H Schönthal; Thomas C Chen
Journal:  J Neurosurg       Date:  2007-03       Impact factor: 5.115

10.  Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report.

Authors:  Katherine B Peters; Roger McLendon; Michael A Morse; James J Vredenburgh
Journal:  Case Rep Oncol       Date:  2010-04-08
View more
  1 in total

1.  Extracranial Intraluminal Extension of Atypical Meningioma within the Internal Jugular Vein.

Authors:  Nizar Taki; Richard O Wein; Harprit Bedi; Carl B Heilman
Journal:  Case Rep Otolaryngol       Date:  2013-02-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.